David R. Guyer Sells 16,520 Shares of Ophthotech Corp (OPHT) Stock

Ophthotech Corp (NASDAQ:OPHT) insider David R. Guyer sold 16,520 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total transaction of $52,698.80. Following the sale, the insider now owns 50,494 shares in the company, valued at $161,075.86. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ophthotech Corp (OPHT) traded up $0.03 during midday trading on Wednesday, hitting $3.30. 361,437 shares of the company were exchanged, compared to its average volume of 558,700. Ophthotech Corp has a twelve month low of $2.24 and a twelve month high of $5.25. The company has a market cap of $118.93, a P/E ratio of 2.12 and a beta of 1.58.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Federated Investors Inc. PA raised its holdings in shares of Ophthotech by 102.3% during the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 28,040 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in shares of Ophthotech by 73.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock valued at $433,000 after acquiring an additional 49,928 shares during the period. Geode Capital Management LLC raised its holdings in shares of Ophthotech by 3.2% during the first quarter. Geode Capital Management LLC now owns 240,571 shares of the biopharmaceutical company’s stock valued at $880,000 after acquiring an additional 7,501 shares during the period. First Manhattan Co. acquired a new stake in shares of Ophthotech during the third quarter valued at approximately $1,201,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Ophthotech by 28.1% during the second quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock valued at $1,672,000 after acquiring an additional 143,349 shares during the period. Institutional investors and hedge funds own 62.48% of the company’s stock.

A number of analysts have commented on OPHT shares. ValuEngine upgraded shares of Ophthotech from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. TheStreet upgraded shares of Ophthotech from an “e+” rating to a “c” rating in a research report on Thursday, November 30th. Stifel Nicolaus restated a “hold” rating and set a $4.00 price target on shares of Ophthotech in a research report on Thursday, September 21st. Finally, Zacks Investment Research upgraded shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target on the stock in a research report on Monday, November 13th.

COPYRIGHT VIOLATION NOTICE: “David R. Guyer Sells 16,520 Shares of Ophthotech Corp (OPHT) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/03/david-r-guyer-sells-16520-shares-of-ophthotech-corp-opht-stock.html.

About Ophthotech

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply